Among the two candidates with high expression in tuft cell-like lung cancers, i.e., BCL2 (Fig. 5C and S9a) and KIT, we selected BCL2 because (1) BCL2 inhibitors (e.g., Venetoclax [ABT-199]) are in clinical use; (2) KIT inhibition is ineffective in KIT-wildtype tumors [38], while such a relationship has not been established in BCL2; (3) BCL2 inhibition has been proposed for SCLC [39], especially ASCL1-SCLC [12], suggesting that it may be clinically relevant in tuft cell-like SCLC as well. Here, ASCL1 is linked to lung cancer.